Palisade Bio financials
$1.45−3.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $250.0K | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $250.0K | $0.00 | — |
| Gross margin | — | — | 100.0% | — | — |
| Operating income | -$18.1M | -$14.9M | -$13.1M | -$15.7M | -$41.9M |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.5M | -$26.6M |
| Net margin | — | — | −4926.4% | — | — |
| Diluted EPS | $-0.30 | $-10.19 | $-27.01 | $-247.95 | $-2546.10 |
| EBITDA | -$18.1M | -$14.9M | -$12.8M | -$15.3M | -$41.9M |
| Operating cash flow | -$10.8M | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Free cash flow | -$10.8M | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Diluted shares | 55.7M | 1.4M | 0.5M | 0.1M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $133.4M | $9.8M | $12.4M | $12.4M | $10.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $87.0K |
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M | $12.5M |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M | $5.1M |
| Shareholders' equity | $129.4M | $7.5M | $11.3M | $12.5M | $7.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology